Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The role of therapeutic drug monitoring for infliximab [IFX] therapy in children with inflammatory bowel disease [IBD] is poorly investigated. We determined if IFX exposure correlates with long-term remission in children.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Crohns Colitis

Title: Journal of Crohn's & colitis

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1876-4479

ISSN (Print): 1873-9946

Publication date (Electronic): Nov 15 2018

Volume: 12

Issue: 11

Affiliations

[1 ] Department of Paediatric Gastroenterology & Hepatology & Nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

[2 ] TARGID, Department of Chronic Diseases, Metabolism and Ageing [CHROMETA], KU Leuven, Leuven, Belgium.

[3 ] Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

[4 ] Department of Gastroenterology & Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Article

Publisher Item ID: 5103494

DOI: 10.1093/ecco-jcc/jjy111

PubMed ID: 30239644

SO-VID: b52eb6ea-5a04-46ce-b80e-b7c0bd4ac8b7

History

Data availability:

Comments

Comment on this article

scite_

Cited by 18

See all cited by